Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Decitabine plus unrelated umbilical cord blood for induction treatment of myelodysplastic syndrome
ChiCTR2000035484Phase 2Not yet recruiting
- Sponsor
- Ruijin Hospital
- Start
- Aug 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of decitabine in myelodysplastic syndrome (MDS), sponsored by Ruijin Hospital. Primary endpoints: Complete Remission Rate and Disease Free Survival. Planned start Aug 2020; status: not yet recruiting.
02
Drugs
decitabine
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on ChiCTR2000035484.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000035484.